Alex A. Adjei

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Physiology

Signal Transduction

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Qi Yingwei; Schild Steven E; Mandrekar Sumithra J; Tan Angelina D; Krook James E; Rowland Kendrith M; Garces Yolanda I; Soori Gamini S; Adjei Alex A; Sloan Jeff A
Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer.
Demmy Todd L; Tomaszewski Garin; Dy Grace K; Yendamuri Sai; Nwogu Chukwumere; Pendyala Lakshmi; Ramnath Nithya; Adjei Alex A
Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results).
Foster Nathan R; Mandrekar Sumithra J; Schild Steven E; Nelson Garth D; Rowland Kendrith M; Deming Richard L; Kozelsky Timothy F; Marks Randolph S; Jett James R; Adjei Alex A
Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Alex A. Adjei (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Qi Yingwei; Schild Steven E; Mandrekar Sumithra J; Tan Angelina D; Krook James E; Rowland Kendrith M; Garces Yolanda I; Soori Gamini S; Adjei Alex A; Sloan Jeff A
Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(9):1075-82.
2009: Demmy Todd L; Tomaszewski Garin; Dy Grace K; Yendamuri Sai; Nwogu Chukwumere; Pendyala Lakshmi; Ramnath Nithya; Adjei Alex A
Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results).
The Annals of thoracic surgery 2009;88(2):385-90; discussion 390-1.
2009: Foster Nathan R; Mandrekar Sumithra J; Schild Steven E; Nelson Garth D; Rowland Kendrith M; Deming Richard L; Kozelsky Timothy F; Marks Randolph S; Jett James R; Adjei Alex A
Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials.
Cancer 2009;115(12):2721-31.
2009: Karp Judith E; Flatten Karen; Feldman Eric J; Greer Jacqueline M; Loegering David A; Ricklis Rebecca M; Morris Lawrence E; Ritchie Ellen; Smith B Douglas; Ironside Valerie; Talbott Timothy; Roboz Gail; Le Son B; Meng Xue Wei; Schneider Paula A; Dai Nga T; Adjei Alex A; Gore Steven D; Levis Mark J; Wright John J; Garrett-Mayer Elizabeth; Kaufmann Scott H
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Blood 2009;113(20):4841-52.
2009: Dy Grace K; Adjei Alex A
Emerging therapeutic targets in non-small cell lung cancer.
Proceedings of the American Thoracic Society 2009;6(2):218-23.
2009: Yang Ping; Mandrekar Sumithra J; Hillman Shauna H; Allen Ziegler Katie L; Sun Zhifu; Wampfler Jason A; Cunningham Julie M; Sloan Jeff A; Adjei Alex A; Perez Edith; Jett James R
Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(4):479-85.
2009: Ma Wen W; Adjei Alex A
Novel agents on the horizon for cancer therapy.
CA: a cancer journal for clinicians 2009;59(2):111-37.
2009: McShane Lisa M; Hunsberger Sally; Adjei Alex A
Effective incorporation of biomarkers into phase II trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(6):1898-905.
2009: Adjei Alex A; Christian Michaele; Ivy Percy
Novel designs and end points for phase II clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(6):1866-72.
2008: Molina Julian R; Kaufmann Scott H; Reid Joel M; Rubin Stephen D; Gálvez-Peralta Marina; Friedman Robert; Flatten Karen S; Koch Kevin M; Gilmer Tona M; Mullin Robert J; Jewell Roxanne C; Felten Sara J; Mandrekar Sumithra; Adjei Alex A; Erlichman Charles
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7900-8.
2008: Wakelee Heather; Kernstine Kemp; Vokes Everett; Schiller Joan; Baas Paul; Saijo Nagahiro; Adjei Alex; Goss Glenwood; Gaspar Laurie; Gandara David R; Choy Hak; Putnam Joe Bill
Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.
Clinical lung cancer 2008;9(6):346-51.
2008: Grothey Axel; Adjei Alex A; Alberts Steve R; Perez Edith A; Jaeckle Kurt A; Loprinzi Charles L; Sargent Daniel J; Sloan Jeff A; Buckner Jan C;
North Central Cancer Treatment Group--achievements and perspectives.
Seminars in oncology 2008;35(5):530-44.
2008: Dy Grace K; Adjei Alex A
Systemic cancer therapy: evolution over the last 60 years.
Cancer 2008;113(7 Suppl):1857-87.
2008: Friday Bret B; Yu Chunrong; Dy Grace K; Smith Paul D; Wang Liang; Thibodeau Stephen N; Adjei Alex A
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Cancer research 2008;68(15):6145-53.
2008: Adjei Alex A
K-ras as a target for lung cancer therapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6 Suppl 2):S160-3.
2008: Yu Chunrong; Friday Bret B; Yang Lin; Atadja Peter; Wigle Dennis; Sarkaria Jann; Adjei Alex A
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Neuro-oncology 2008;10(3):309-19.
2008: Molina Julian R; Yang Ping; Cassivi Stephen D; Schild Steven E; Adjei Alex A
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Mayo Clinic proceedings. Mayo Clinic 2008;83(5):584-94.
2008: Adjei Alex A; Cohen Roger B; Franklin Wilbur; Morris Clive; Wilson David; Molina Julian R; Hanson Lorelei J; Gore Lia; Chow Laura; Leong Stephen; Maloney Lara; Gordon Gilad; Simmons Heidi; Marlow Allison; Litwiler Kevin; Brown Suzy; Poch Gregory; Kane Katie; Haney Jerry; Eckhardt S Gail
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2139-46.
2008: Johnson Elizabeth A; Marks Randolph S; Mandrekar Sumithra J; Hillman Shauna L; Hauge Mark D; Bauman Mitchel D; Wos Edward J; Moore Dennis F; Kugler John W; Windschitl Harold E; Graham David L; Bernath Albert M; Fitch Tom R; Soori Gamini S; Jett James R; Adjei Alex A; Perez Edith A
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
Lung cancer (Amsterdam, Netherlands) 2008;60(2):200-7.
2008: Gilbert Judith A; Goetz Matthew P; Reynolds Carol A; Ingle James N; Giordano Karin F; Suman Vera J; Blair Hilary E; Jenkins Robert B; Lingle Wilma L; Reinholz Monica M; Adjei Alex A; Ames Matthew M
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
Molecular cancer therapeutics 2008;7(4):944-51.
2008: Lai Jin-Ping; Sandhu Dalbir S; Yu Chunrong; Han Tao; Moser Catherine D; Jackson Kenard K; Guerrero Ruben Bonilla; Aderca Ileana; Isomoto Hajime; Garrity-Park Megan M; Zou Hongzhi; Shire Abdirashid M; Nagorney David M; Sanderson Schuyler O; Adjei Alex A; Lee Ju-Seog; Thorgeirsson Snorri S; Roberts Lewis R
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.
Hepatology (Baltimore, Md.) 2008;47(4):1211-22.
2008: Okuno Scott H; Delaune Robert; Sloan Jeff A; Foster Nathan R; Maurer Matthew J; Aubry Marie-Christine; Rowland Kendrith M; Soori Gamini S; Nikcevich Daniel A; Kardinal Carl G; Northfelt Donald W; Adjei Alex A;
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
Cancer 2008;112(8):1772-9.
2008: Langer Corey J; Wakelee Heather; Schiller Joan; Choy Hak; Shepherd Frances; Vokes Everett E; Adjei Alex A; Baas Paul; Saijo Nagahiro; Gandara David R
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
Clinical lung cancer 2008;9(2):85-91.
2008: Sher Taimur; Dy Grace K; Adjei Alex A
Small cell lung cancer.
Mayo Clinic proceedings. Mayo Clinic 2008;83(3):355-67.
2008: Wakelee Heather; Langer Corey; Vokes Everett; Schiller Joan; Baas Paul; Saijo Nagahiro; Adjei Alex; Shepherd Frances; Choy Hak; Gandara David R
Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer.
Clinical lung cancer 2008;9(1):9-15.
2008: Friday Bret B; Adjei Alex A
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):342-6.
2008: Furimsky Anna M; Green Carol E; Sharp Lewanne E Hunt; Catz Paul; Adjei Araba A; Parman Toufan; Kapetanovic Izet M; Weinshilboum Richard M; Iyer Lalitha V
Effect of resveratrol on 17beta-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(1):129-36.
2008: Furth Alfred F; Mandrekar Sumithra J; Tan Angelina D; Rau Andrea; Felten Sara J; Ames Matthew M; Adjei Alex A; Erlichman Charles; Reid Joel M
A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.
Cancer chemotherapy and pharmacology 2008;61(1):39-45.
2007: Haluska Paul; Shaw Heather M; Batzel Gretchen N; Yin Donghua; Molina Julian R; Molife L Rhoda; Yap Timothy A; Roberts M Luisa; Sharma Amarnath; Gualberto Antonio; Adjei Alex A; de Bono Johann S
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5834-40.
2007: Meng Xue Wei; Lee Sun-Hee; Dai Haiming; Loegering David; Yu Chunrong; Flatten Karen; Schneider Paula; Dai Nga T; Kumar Shaji K; Smith B Douglas; Karp Judith E; Adjei Alex A; Kaufmann Scott H
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
The Journal of biological chemistry 2007;282(41):29831-46.
2007: Barton Debra L; Loprinzi Charles L; Atherton Pamela; Raymond Jane; Shanafelt Tait; Hines Stephanie; Palmieri Fran; Rummans Teresa; Adjei Alex A; Sloan Jeff
Phase II Evaluation of Desipramine for the Treatment of Hot Flashes.
Supportive cancer therapy 2007;4(4):219-24.
2007: Leil Tarek A; Endo Chiaki; Adjei Araba A; Dy Grace K; Salavaggione Oreste E; Reid Joel R; Ames Matthew M; Adjei Alex A
Identification and characterization of genetic variation in the folylpolyglutamate synthase gene.
Cancer research 2007;67(18):8772-82.
2007: Leil Tarek A; Endo Chiaki; Adjei Araba A; Dy Grace K; Salavaggione Oreste E; Reid Joel R; Ames Matthew M; Adjei Alex A
Identification and characterization of genetic variation in the folylpolyglutamate synthase gene.
Cancer research 2007;67(18):8772-82.
2007: Schild Steven E; Bonner James A; Hillman Shauna; Kozelsky Timothy F; Vigliotti Antonio P G; Marks Randolph S; Graham David L; Soori Gamini S; Kugler John W; Tenglin Richard C; Wender Donald B; Adjei Alex
Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3124-9.
2007: Schild Steven E; Mandrekar Sumithra J; Jatoi Aminah; McGinnis William L; Stella Phillip J; Deming Richard L; Jett James R; Garces Yolanda I; Allen Katie L; Adjei Alex A;
The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer.
Cancer 2007;110(2):363-8.
2007: de Bono Johann S; Attard Gerhardt; Adjei Alex; Pollak Michael N; Fong Peter C; Haluska Paul; Roberts Luisa; Melvin Carrie; Repollet Madeline; Chianese David; Connely Mark; Terstappen Leon W M M; Gualberto Antonio
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3611-6.
2007: Adjei Alex A; Molina Julian R; Mandrekar Sumithra J; Marks Randolph; Reid Joel R; Croghan Gary; Hanson Lorelei J; Jett James R; Xia Chenghua; Lathia Chetan; Simantov Ronit
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2684-91.
2007: Hebbring Scott J; Adjei Araba A; Baer Janel L; Jenkins Gregory D; Zhang Jianping; Cunningham Julie M; Schaid Daniel J; Weinshilboum Richard M; Thibodeau Stephen N
Human SULT1A1 gene: copy number differences and functional implications.
Human molecular genetics 2007;16(5):463-70.
2007: Adjei Alex A
Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.
Clinical lung cancer 2007;8 Suppl 2():S74-8.
2007: Yu Chunrong; Friday Bret B; Lai Jin-Ping; McCollum Andrea; Atadja Peter; Roberts Lewis R; Adjei Alex A
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1140-8.
2007: Lancet Jeffrey E; Gojo Ivana; Gotlib Jason; Feldman Eric J; Greer Jacqueline; Liesveld Jane L; Bruzek Laura M; Morris Lawrence; Park Youn; Adjei Alex A; Kaufmann Scott H; Garrett-Mayer Elizabeth; Greenberg Peter L; Wright John J; Karp Judith E
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Blood 2007;109(4):1387-94.
2007: Ma Cynthia; Mandrekar Sumithra J; Alberts Steven R; Croghan Gary A; Jatoi Aminah; Reid Joel M; Hanson Lorelei J; Bruzek Laura; Tan Angelina D; Pitot Henry C; Erlichman Charles; Wright John J; Adjei Alex A
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 2007;59(2):207-15.
2007: Adjei Alex A; Rajkumar S Vincent; Tefferi Ayalew
Cancer symposium for the practitioner: introduction to solid tumors.
Mayo Clinic proceedings. Mayo Clinic 2007;82(1):107-9.
2007: Davis Ian D; Wiseman Gregory A; Lee Fook-Thean; Gansen Denise N; Hopkins Wendie; Papenfuss Anthony T; Liu Zhanqi; Moynihan Timothy J; Croghan Gary A; Adjei Alex A; Hoffman Eric W; Ingle James N; Old Lloyd J; Scott Andrew M
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
Cancer immunity : a journal of the Academy of Cancer Immunology 2007;7():13.
2006: Nowakowski Grzegorz S; McCollum Andrea K; Ames Matthew M; Mandrekar Sumithra J; Reid Joel M; Adjei Alex A; Toft David O; Safgren Stephanie L; Erlichman Charles
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6087-93.
2006: Molina Julian R; Adjei Alex A; Jett James R
Advances in chemotherapy of non-small cell lung cancer.
Chest 2006;130(4):1211-9.
2006: Papadimitrakopoulou Vassiliki; Adjei Alex A
The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(7):749-51.
2006: Yu Chunrong; Friday Bret B; Lai Jin-Ping; Yang Lin; Sarkaria Jann; Kay Neil E; Carter Christopher A; Roberts Lewis R; Kaufmann Scott H; Adjei Alex A
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Molecular cancer therapeutics 2006;5(9):2378-87.
2006: Adjei Alex A
What is the right dose? The elusive optimal biologic dose in phase I clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(25):4054-5.
2006: Mandrekar Sumithra J; Schild Steven E; Hillman Shauna L; Allen Katie L; Marks Randolph S; Mailliard James A; Krook James E; Maksymiuk Andrew W; Chansky Kari; Kelly Karen; Adjei Alex A; Jett James R
A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials.
Cancer 2006;107(4):781-92.
2006: Pitot Henry C; Adjei Alex A; Reid Joel M; Sloan Jeff A; Atherton Pamela J; Rubin Joseph; Alberts Steven R; Duncan Barbara A; Denis Louis; Schaaf Larry J; Yin Donghua; Sharma Amarnath; McGovren Patrick; Miller Langdon L; Erlichman Charles
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2006;58(2):165-72.
2006: Mandrekar Sumithra J; Northfelt Donald W; Schild Steven E; Foster Nathan R; Bot Brian; Marks Randolph S; Mailliard James A; Krook James E; Maksymiuk Andrew W; Adjei Alex A; Jett James R
Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(6):556-63.
2006: Adjei Alex A
Novel combinations based on epidermal growth factor receptor inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 2):4446s-4450s.
2006: Lynch Thomas J; Adjei Alex A; Bunn Paul A; Eisen Tim G; Engelman Jeffrey; Goss Glenwood D; Haber Daniel A; Heymach John V; Jänne Pasi A; Johnson Bruce E; Johnson David H; Lilenbaum Rogerio C; Meyerson Matthew; Sandler Alan B; Sequist Lecia V; Settleman Jeffrey; Wong Kwok-Kin; Hart Carol S
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 2):4365s-4371s.
2006: Schild Steven E; McGinnis William L; Graham David; Hillman Shauna; Fitch Tom R; Northfelt Donald; Garces Yolanda I; Shahidi Homayoon; Tschetter Loren K; Schaefer Paul L; Adjei Alex; Jett James
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.
International journal of radiation oncology, biology, physics 2006;65(4):1106-11.
2006: Molina Julian R; Nikcevich Daniel; Hillman Shauna; Geyer Susan; Drevyanko Timothy; Jett James; Verdirame Joseph; Tazelaar Henry; Rowland Kendrith; Wos Edward; Kutteh Leila; Nair Suresh; Fitch Tom; Flynn Patrick; Stella Philip; Adjei Alex A
A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer.
Cancer investigation 2006;24(4):382-9.
2006: Holash Jocelyn; Thurston Gavin; Rudge John S; Yancopoulos George D; Adjei Alex A; Bergers Gabriele; Pytowski Bronislaw; Pegram Mark; Gordon Michael S
Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.
Cancer metastasis reviews 2006;25(2):243-52.
2006: Lai Jin-Ping; Yu Chunrong; Moser Catherine D; Aderca Ileana; Han Tao; Garvey Thomas D; Murphy Linda M; Garrity-Park Megan M; Shridhar Viji; Adjei Alex A; Roberts Lewis R
SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Gastroenterology 2006;130(7):2130-44.
2006: Adjei A A
Clinical studies of pemetrexed and gemcitabine combinations.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 5():v29-32.
2006: Dy Grace K; Adjei Alex A
Angiogenesis inhibitors in lung cancer: a promise fulfilled.
Clinical lung cancer 2006;7 Suppl 4():S145-9.
2006: Erlichman Charles; Hidalgo Manuel; Boni Joseph P; Martins Patricia; Quinn Susan E; Zacharchuk Charles; Amorusi Peter; Adjei Alex A; Rowinsky Eric K
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2252-60.
2006: Ma C X; Steen P; Rowland K M; Niedringhaus R D; Fitch T R; Kugler J W; Hillman D W; Perez E A; Ingle J N; Adjei A A
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(2):226-31.
2006: Barton Debra L; Loprinzi Charles; Atherton Pamela J; Kottschade Lisa; Collins Mary; Carpenter Paul; Adjei Alex; Rummans Teresa A; Shanafelt Tait; Christensen Brad; Sloan Jeff
Dehydroepiandrosterone for the treatment of hot flashes: a pilot study.
Supportive cancer therapy 2006;3(2):91-7.
2006: Molina Julian R; Adjei Alex A
The Ras/Raf/MAPK pathway.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(1):7-9.
2005: Jatoi Aminah; Hillman Shauna; Stella Philip; Green Erin; Adjei Alex; Nair Suresh; Perez Edith; Amin Bipinkur; Schild Steven E; Castillo Rene; Jett James R;
Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9113-9.
2005: Ma Cynthia X; Adjei Araba A; Salavaggione Oreste E; Coronel Josefa; Pelleymounter Linda; Wang Liewei; Eckloff Bruce W; Schaid Daniel; Wieben Eric D; Adjei Alex A; Weinshilboum Richard M
Human aromatase: gene resequencing and functional genomics.
Cancer research 2005;65(23):11071-82.
2005: Ma Cynthia X; Adjei Araba A; Salavaggione Oreste E; Coronel Josefa; Pelleymounter Linda; Wang Liewei; Eckloff Bruce W; Schaid Daniel; Wieben Eric D; Adjei Alex A; Weinshilboum Richard M
Human aromatase: gene resequencing and functional genomics.
Cancer research 2005;65(23):11071-82.
2005: Ji Yuan; Salavaggione Oreste E; Wang Liewei; Adjei Araba A; Eckloff Bruce; Wieben Eric D; Weinshilboum Richard M
Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics.
Journal of neurochemistry 2005;95(6):1766-76.
2005: Dy Grace K; Mandrekar Sumithra; Peethambaram Prema P; Okuno Scott H; Croghan Gary C; Hanson Lorelei J; Furth Alfred; Adjei Alex A
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2005;56(6):623-8.
2005: Adjei Alex A
The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy.
Clinical lung cancer 2005;7(3):221-3.
2005: Sellers Thomas A; Schildkraut Joellen M; Pankratz V Shane; Vierkant Robert A; Fredericksen Zachary S; Olson Janet E; Cunningham Julie; Taylor William; Liebow Mark; McPherson Carol; Hartmann Lynn C; Pal Tuya; Adjei Araba A
Estrogen bioactivation, genetic polymorphisms, and ovarian cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(11 Pt 1):2536-43.
2005: Friday Bret B; Adjei Alex A
K-ras as a target for cancer therapy.
Biochimica et biophysica acta 2005;1756(2):127-44.
2005: Dy G K; Miller A A; Mandrekar S J; Aubry M-C; Langdon R M; Morton R F; Schild S E; Jett J R; Adjei A A
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(11):1811-6.
2005: Adjei Alex A
Sequencing bortezomib with chemotherapy and targeted agents.
Clinical lung cancer 2005;7 Suppl 2():S56-8.
2005: Loprinzi Charles L; Flynn Patrick J; Carpenter Lisa A; Atherton Pam; Barton Debra L; Shanafelt Tait D; Rummans Teresa A; Sloan Jeff A; Adjei Alex A; Mincey Betty A; Fitch Tom R; Collins Mary
Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine.
Journal of palliative medicine 2005;8(5):924-30.
2005: Yu Chunrong; Bruzek Laura M; Meng Xue Wei; Gores Gregory J; Carter Christopher A; Kaufmann Scott H; Adjei Alex A
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
Oncogene 2005;24(46):6861-9.
2005: Kaufmann Scott H; Karp Judith E; Letendre Louis; Kottke Timothy J; Safgren Stephanie; Greer Jackie; Gojo Ivana; Atherton Pamela; Svingen Phyllis A; Loegering David A; Litzow Mark R; Sloan Jeff A; Reid Joel M; Ames Matthew M; Adjei Alex A; Erlichman Charles
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6641-9.
2005: Adjei Alex A
Targeting multiple signal transduction pathways in lung cancer.
Clinical lung cancer 2005;7 Suppl 1():S39-44.
2005: Ma Cynthia X; Nair Suresh; Thomas Sachdev; Mandrekar Sumithra J; Nikcevich Daniel A; Rowland Kendrith M; Fitch Tom R; Windschitl Harold E; Hillman Shauna L; Schild Steven E; Jett James R; Obasaju Coleman; Adjei Alex A;
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5929-37.
2005: Bible Keith C; Lensing Janet L; Nelson Sacha A; Lee Yean K; Reid Joel M; Ames Matthew M; Isham Crescent R; Piens Jill; Rubin Stacie L; Rubin Joseph; Kaufmann Scott H; Atherton Pamela J; Sloan Jeffrey A; Daiss Michelle K; Adjei Alex A; Erlichman Charles
Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5935-41.
2005: Tefferi Ayalew; Rajkumar S Vincent; Adjei Alex A
Introduction to a cancer symposium for the practitioner.
Mayo Clinic proceedings. Mayo Clinic 2005;80(8):1085-6.
2005: Adjei Alex A; Hidalgo Manuel
Treating cancer by blocking cell signals.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5279-80.
2005: Giordano Karin F; Jatoi Aminah; Adjei Alex A; Creagan Edward T; Croghan Gary; Frytak Stephen; Jett James R; Marks Randolph; Molina Julian; Okuno Scott; Richardson Ronald L
Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution.
Lung cancer (Amsterdam, Netherlands) 2005;49(2):209-15.
2005: Lorusso Patricia M; Adjei Alex A; Varterasian Mary; Gadgeel Shirish; Reid Joel; Mitchell David Y; Hanson Lorelei; DeLuca Pamela; Bruzek Laura; Piens Jill; Asbury Peggy; Van Becelaere Keri; Herrera Roman; Sebolt-Leopold Judith; Meyer Mark B
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5281-93.
2005: Adjei Alex A; Hidalgo Manuel
Intracellular signal transduction pathway proteins as targets for cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5386-403.
2005: Bruzek Laura M; Poynter Jenny N; Kaufmann Scott H; Adjei Alex A
Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
Molecular pharmacology 2005;68(2):477-86.
2005: Yang Ping; Allen Mark S; Aubry Marie C; Wampfler Jason A; Marks Randolph S; Edell Eric S; Thibodeau Stephen; Adjei Alex A; Jett James; Deschamps Claude
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003.
Chest 2005;128(1):452-62.
2005: Markovic Svetomir N; Geyer Susan M; Dawkins Fitzroy; Sharfman William; Albertini Mark; Maples William; Fracasso Paula M; Fitch Tom; Lorusso Patricia; Adjei Alex A; Erlichman Charles
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Cancer 2005;103(12):2584-9.
2005: Schild Steven E; Stella Philip J; Brooks Burke J; Mandrekar Sumithra; Bonner James A; McGinnis William L; Mailliard James A; Krook James E; Deming Richard L; Adjei Alex A; Jatoi Aminah; Jett James R
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly.
Cancer 2005;103(11):2349-54.
2005: Dy Grace K; Suri Ajit; Reid Joel M; Sloan Jeff A; Pitot Henry C; Alberts Steven R; Goldberg Richard M; Atherton Pamela J; Hanson Lorelei J; Burch Patrick A; Rubin Joseph; Erlichman Charles; Adjei Alex A
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;55(6):522-30.
2005: Ghobrial Irene M; Witzig Thomas E; Adjei Alex A
Targeting apoptosis pathways in cancer therapy.
CA: a cancer journal for clinicians 2005;55(3):178-94.
2005: Dy Grace K; Thomas James P; Wilding George; Bruzek Laura; Mandrekar Sumithra; Erlichman Charles; Alberti Dona; Binger Kim; Pitot Henry C; Alberts Steven R; Hanson Lorelei J; Marnocha Rebecca; Tutsch Kendra; Kaufmann Scott H; Adjei Alex A
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3410-6.
2005: Dy Grace K; Bruzek Laura M; Croghan Gary A; Mandrekar Sumithra; Erlichman Charles; Peethambaram Prema; Pitot Henry C; Hanson Lorelei J; Reid Joel M; Furth Alfred; Cheng Shinta; Martell Robert E; Kaufmann Scott H; Adjei Alex A
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1877-83.
2005: Goetz Matthew P; Toft David; Reid Joel; Ames Matthew; Stensgard Bridget; Safgren Stephanie; Adjei Araba A; Sloan Jeff; Atherton Pamela; Vasile Vlad; Salazaar Sandra; Adjei Alex; Croghan Gary; Erlichman Charles
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1078-87.
2005: Goetz Matthew P; Toft David; Reid Joel; Ames Matthew; Stensgard Bridget; Safgren Stephanie; Adjei Araba A; Sloan Jeff; Atherton Pamela; Vasile Vlad; Salazaar Sandra; Adjei Alex; Croghan Gary; Erlichman Charles
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1078-87.
2005: Dy Grace K; Adjei Alex A
Obstacles and opportunities in the clinical development of targeted therapeutics.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 2005;63():19-41.
2005: Adjei Alex A
Farnesyltransferase inhibitors.
Cancer chemotherapy and biological response modifiers 2005;22():123-33.
2004: Dy Grace K; Bekele Lishan; Hanson Lorelei J; Furth Alfred; Mandrekar Sumithra; Sloan Jeff A; Adjei Alex A
Complementary and alternative medicine use by patients enrolled onto phase I clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4810-5.
2004: Belani Chandra P; Adjei Alex
Combining targeted agents in lung cancer.
Clinical lung cancer 2004;6(3):138.
2004: Rinehart John; Adjei Alex A; Lorusso Patricia M; Waterhouse David; Hecht J Randolph; Natale Ronald B; Hamid Oday; Varterasian Mary; Asbury Peggy; Kaldjian Eric P; Gulyas Stephen; Mitchell David Y; Herrera Roman; Sebolt-Leopold Judith S; Meyer Mark B
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(22):4456-62.
2004: Adjei Alex A
Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4276s-4280s.
2004: Lynch Thomas J; Adjei Alex A; Bunn Paul A; DuBois Raymond N; Gandara David R; Giaccone Giuseppe; Govindan Ramaswamy; Herbst Roy S; Johnson Bruce E; Khuri Fadlo R; Perez-Soler Roman; Rosell Rafael; Rowinsky Eric K; Sandler Alan B; Scagliotti Giorgio V; Schiller Joan H; Shapiro Geoffrey I; Socinski Mark A; Hart Carol S
Novel agents in the treatment of lung cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4199s-4204s.
2004: Alsina Melissa; Fonseca Rafael; Wilson Edward F; Belle A Nelida; Gerbino Elvira; Price-Troska Tammy; Overton Rose M; Ahmann Gregory; Bruzek Laura M; Adjei Alex A; Kaufmann Scott H; Wright John J; Sullivan Daniel; Djulbegovic Benjamin; Cantor Alan B; Greipp Philip R; Dalton William S; Sebti Saïd M
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Blood 2004;103(9):3271-7.
2004: Adjei Alex A
Pharmacology and mechanism of action of pemetrexed.
Clinical lung cancer 2004;5 Suppl 2():S51-5.
2004: Sebti Said M; Adjei Alex A
Farnesyltransferase inhibitors.
Seminars in oncology 2004;31(1 Suppl 1):28-39.
2003: Chandra Joya; Hackbarth Jennifer; Le Son; Loegering David; Bone Nancy; Bruzek Laura M; Narayanan Ven L; Adjei Alex A; Kay Neil E; Tefferi Ayalew; Karp Judith E; Sausville Edward A; Kaufmann Scott H
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.
Blood 2003;102(13):4512-9.
2003: Goetz Matthew P; Erlichman Charles; Windebank Anthony J; Reid Joel M; Sloan Jeffrey A; Atherton Pamela; Adjei Alex A; Rubin Joseph; Pitot Henry; Galanis Evanthia; Ames Matthew M; Goldberg Richard M
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(20):3761-9.
2003: Adjei Araba A; Thomae Bianca A; Prondzinski Janel L; Eckloff Bruce W; Wieben Eric D; Weinshilboum Richard M
Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics.
British journal of pharmacology 2003;139(8):1373-82.
2003: Adjei Alex A
An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.
Lung cancer (Amsterdam, Netherlands) 2003;41 Suppl 1():S55-62.
2003: Molina Julian R; Adjei Alex A
The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
Clinical lung cancer 2003;5(1):21-7.
2003: Adjei Alex A; Rowinsky Eric K
Novel anticancer agents in clinical development.
Cancer biology & therapy 2003;2(4 Suppl 1):S5-15.
2003: Adjei Alex A; Croghan Gary A; Erlichman Charles; Marks Randolph S; Reid Joel M; Sloan Jeff A; Pitot Henry C; Alberts Steven R; Goldberg Richard M; Hanson Lorelei J; Bruzek Laura M; Atherton Pamela; Thibault Alain; Palmer Peter A; Kaufmann Scott H
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2520-6.
2003: Shanafelt Tait; Adjei Alex; Meyskens Frank L
When your favorite patient relapses: physician grief and well-being in the practice of oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2616-9.
2003: Scott Andrew M; Wiseman Greg; Welt Sydney; Adjei Alex; Lee Fook-Thean; Hopkins Wendie; Divgi Chaitan R; Hanson Lorelei H; Mitchell Paul; Gansen Denise N; Larson Steven M; Ingle James N; Hoffman Eric W; Tanswell Paul; Ritter Gerd; Cohen Leonard S; Bette Peter; Arvay Lisa; Amelsberg Andree; Vlock Dan; Rettig Wolfgang J; Old Lloyd J
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1639-47.
2003: Adjei Alex A; Mauer Ann; Bruzek Laura; Marks Randolph S; Hillman Shauna; Geyer Susan; Hanson Lorelei J; Wright John J; Erlichman Charles; Kaufmann Scott H; Vokes Everett E
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1760-6.
2003: Adjei Alex A
Pemetrexed (Alimta): a novel multitargeted antifolate agent.
Expert review of anticancer therapy 2003;3(2):145-56.
2003: Dees E Claire; Rowinsky Eric K; Noe Dennis A; O'Reilly Seamus; Adjei Alex A; Elza-Brown Kathy; Donehower Ross C
A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.
Investigational new drugs 2003;21(1):75-84.
2003: Adjei Alex A
Current data with pemetrexed (Alimta) in non-small-cell lung cancer.
Clinical lung cancer 2003;4 Suppl 2():S64-7.
2003: Adjei Alex A; Dy Grace K; Erlichman Charles; Reid Joel M; Sloan Jeff A; Pitot Henry C; Alberts Steven R; Goldberg Richard M; Hanson Lorelei J; Atherton Pamela J; Watanabe Tanya; Geary Richard S; Holmlund Jon; Dorr F Andrew
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):115-23.
2003: Adjei Alex A
Farnesyltransferase inhibitors.
Cancer chemotherapy and biological response modifiers 2003;21():127-44.
2003: Adjei Alex A
Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
Methods in molecular medicine 2003;85():141-5.
2002: Adjei Alex A
Preclinical and clinical studies with combinations of pemetrexed and gemcitabine.
Seminars in oncology 2002;29(6 Suppl 18):30-4.
2002: Shanafelt Tait D; Barton Debra L; Adjei Alex A; Loprinzi Charles L
Pathophysiology and treatment of hot flashes.
Mayo Clinic proceedings. Mayo Clinic 2002;77(11):1207-18.
2002: Ghobrial Irene M; Adjei Alex A
Inhibitors of the ras oncogene as therapeutic targets.
Hematology/oncology clinics of North America 2002;16(5):1065-88.
2002: Goldberg R M; Kaufmann S H; Atherton P; Sloan J A; Adjei A A; Pitot H C; Alberts S R; Rubin J; Miller L L; Erlichman C
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(10):1674-80.
2002: Adjei Alex A
"Targeted" therapies for non-small cell lung cancer.
Clinical lung cancer 2002;4(2):124.
2002: Haluska P; Dy G K; Adjei A A
Farnesyl transferase inhibitors as anticancer agents.
European journal of cancer (Oxford, England : 1990) 2002;38(13):1685-700.
2002: Adjei Alex A; Reid Joel M; Erlichman Charles; Sloan Jeff A; Pitot Henry C; Alberts Steven R; Goldberg Richard M; Hanson Lorelei J; Ruben Stacie; Boemer Scott A; Atherton Pamela; Ames Matthew M; Kaufmann Scott H
A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.
Investigational new drugs 2002;20(3):297-304.
2002: Perez E A; Geeraerts L; Suman V J; Adjei A A; Baron A T; Hatfield A K; Maihle N; Michalak J C; Kuross S A; Kugler J W; Lafky J M; Ingle J N
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(8):1225-35.
2002: Dy Grace K; Adjei Alex A
The role of farnesyltransferase inhibitors in lung cancer therapy.
Clinical lung cancer 2002;4(1):57-62.
2002: Dy Grace K; Adjei Alex A
Novel targets for lung cancer therapy: part II.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(13):3016-28.
2002: Dy Grace K; Adjei Alex A
Novel targets for lung cancer therapy: part I.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(12):2881-94.
2002: Markovic Svetomir N; Suman Vera J; Vukov Allen M; Fitch Tom R; Hillman David W; Adjei Alex A; Alberts Steven R; Kaur Judith S; Braich Theodore A; Leitch John M; Creagan Edward T
Phase II trial of KW2189 in patients with advanced malignant melanoma.
American journal of clinical oncology 2002;25(3):308-12.
2002: Adjei Alex A
Pemetrexed (Alimta) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes.
Clinical breast cancer 2002;3 Suppl 1():21-3.
2002: Adjei Alex A
Pemetrexed in the treatment of selected solid tumors.
Seminars in oncology 2002;29(2 Suppl 5):50-3.
2002: Adjei Araba A; Weinshilboum Richard M
Catecholestrogen sulfation: possible role in carcinogenesis.
Biochemical and biophysical research communications 2002;292(2):402-8.
2002: Adjei Alex A; Reid Joel M; Diasio Robert B; Sloan Jeff A; Smith Deborah A; Rubin Joseph; Pitot Henry C; Alberts Steven R; Goldberg Richard M; Hanson Lorelei J; Atherton Pamela; Ames Matthew M; Erlichman Charles
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1683-91.
2002: Pitot Henry C; Reid Joel M; Sloan Jeff A; Ames Matthew M; Adjei Alex A; Rubin Joseph; Bagniewski Pamela G; Atherton Pamela; Rayson Daniel; Goldberg Richard M; Erlichman Charles
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):712-7.
2002: Adjei Alex A
Farnesyltransferase inhibitors.
Cancer chemotherapy and biological response modifiers 2002;20():151-67.
2002: Dy Grace K; Adjei Alex A
Farnesyltransferase inhibitors in breast cancer therapy.
Cancer investigation 2002;20 Suppl 2():30-7.
2001: Dy G K; Haluska P; Adjei A A
Novel pharmacological agents in clinical development for solid tumours.
Expert opinion on investigational drugs 2001;10(12):2059-88.
2001: Adjei A A
Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 4():S103-5.
2001: Karp J E; Kaufmann S H; Adjei A A; Lancet J E; Wright J J; End D W
Current status of clinical trials of farnesyltransferase inhibitors.
Current opinion in oncology 2001;13(6):470-6.
2001: Adjei A A
Ras signaling pathway proteins as therapeutic targets.
Current pharmaceutical design 2001;7(16):1581-94.
2001: Daniels G A; Adjei A A
Advances in systemic therapy of small cell cancer of the lung.
Expert review of anticancer therapy 2001;1(2):211-21.
2001: Porrata L F; Adjei A A
The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours.
British journal of cancer 2001;85(4):484-9.
2001: Bekele L; Vidal Vazquez M; Adjei A A
Systemic chemotherapy in patients with renal failure.
American journal of clinical oncology 2001;24(4):382-4.
2001: Adjei A A
Blocking oncogenic Ras signaling for cancer therapy.
Journal of the National Cancer Institute 2001;93(14):1062-74.
2001: Galanis E; Goldberg R; Reid J; Atherton P; Sloan J; Pitot H; Rubin J; Adjei A A; Burch P; Safgren S L; Witzig T E; Ames M M; Erlichman C
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):701-7.
2001: Alberts S R; Erlichman C; Sloan J; Okuno S H; Burch P A; Rubin J; Pitot H C; Goldberg R M; Adjei A A; Atherton P J; Kaufmann S H
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):627-31.
2001: Adjei A A; Davis J N; Bruzek L M; Erlichman C; Kaufmann S H
Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1438-45.
2001: Erlichman C; Adjei A A; Alberts S R; Sloan J A; Goldberg R M; Pitot H C; Rubin J; Atherton P J; Klee G G; Humphrey R
Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(3):389-95.
2001: Haluska P; Adjei A A
Receptor tyrosine kinase inhibitors.
Current opinion in investigational drugs (London, England : 2000) 2001;2(2):280-6.
2001: Adjei A A
Gemcitabine and Pemetrexed disodium in treating breast cancer.
Oncology (Williston Park, N.Y.) 2001;15(2 Suppl 3):34-7.
2001: Xu Z; Wood T C; Adjei A A; Weinshilboum R M
Human 3'-phosphoadenosine 5'-phosphosulfate synthetase: radiochemical enzymatic assay, biochemical properties, and hepatic variation.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(2):172-8.
2001: Adjei A A
Farnesyltransferase inhibitors.
Cancer chemotherapy and biological response modifiers 2001;19():149-64.
2000: Adjei A A
Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(10):1335-41.
2000: Adjei A A
Management of small cell cancer of the lung.
Current opinion in pulmonary medicine 2000;6(4):384-90.
2000: Adjei A A; Davis J N; Erlichman C; Svingen P A; Kaufmann S H
Comparison of potential markers of farnesyltransferase inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(6):2318-25.
2000: Pitot H C; Goldberg R M; Reid J M; Sloan J A; Skaff P A; Erlichman C; Rubin J; Burch P A; Adjei A A; Alberts S A; Schaaf L J; Elfring G; Miller L L
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(6):2236-44.
2000: Adjei A A; Erlichman C; Davis J N; Cutler D L; Sloan J A; Marks R S; Hanson L J; Svingen P A; Atherton P; Bishop W R; Kirschmeier P; Kaufmann S H
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
Cancer research 2000;60(7):1871-7.
2000: Adjei A A; Erlichman C; Sloan J A; Reid J M; Pitot H C; Goldberg R M; Peethambaram P; Atherton P; Hanson L J; Alberts S R; Jett J
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(8):1748-57.
2000: Adjei A A
Signal transduction pathway targets for anticancer drug discovery.
Current pharmaceutical design 2000;6(4):361-78.
2000: Adjei A A; Klein C E; Kastrissios H; Goldberg R M; Alberts S R; Pitot H C; Sloan J A; Reid J M; Hanson L J; Atherton P; Rubin J; Erlichman C
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):1116-23.
1999: Adjei A A; Argiris A; Murren J R
Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
Seminars in oncology 1999;26(5 Suppl 16):32-40; discussion 41-2.
1999: Adjei A A
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
British journal of clinical pharmacology 1999;48(3):265-77.
1999: Adjei A A; Marks R S; Bonner J A
Current guidelines for the management of small cell lung cancer.
Mayo Clinic proceedings. Mayo Clinic 1999;74(8):809-16.
1999: Adjei A A; Erlichman C
A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer.
Seminars in oncology 1999;26(2 Suppl 6):94-8.
1999: Rayson D; Adjei A A; Suman V J; Wold L E; Ingle J N
Metaplastic breast cancer: prognosis and response to systemic therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):413-9.
1999: Pitot H C; McElroy E A; Reid J M; Windebank A J; Sloan J A; Erlichman C; Bagniewski P G; Walker D L; Rubin J; Goldberg R M; Adjei A A; Ames M M
Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(3):525-31.
1999: Go R S; Adjei A A
Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):409-22.
1999: Adjei A A
Current status of pyrazoloacridine as an anticancer agent.
Investigational new drugs 1999;17(1):43-8.
1998: Adjei A A; Charron M; Rowinsky E K; Svingen P A; Miller J; Reid J M; Sebolt-Leopold J; Ames M M; Kaufmann S H
Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):683-91.
1998: Rajkumar S V; Adjei A A
A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer.
Cancer treatment reviews 1998;24(1):35-53.
1997: Adjei A A; Budihardjo I I; Rowinsky E K; Kottke T J; Svingen P A; Buckwalter C A; Grochow L B; Donehower R C; Kaufmann S H
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):761-70.
1996: Baker S D; Khor S P; Adjei A A; Doucette M; Spector T; Donehower R C; Grochow L B; Sartorius S E; Noe D A; Hohneker J A; Rowinsky E K
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3085-96.
1994: Rowinsky E K; Adjei A; Donehower R C; Gore S D; Jones R J; Burke P J; Cheng Y C; Grochow L B; Kaufmann S H
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2193-203.
1992: Adjei A A; Dagnino L; Wong M M; Paterson A R
Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine.
Cancer chemotherapy and pharmacology 1992;31(1):71-5.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Alex A. Adjei

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Alex A. Adjei (preview)

All Publications